Nikolay Savchuk - Traws Pharma COO Director
| TRAW Stock | 7.17 0.00 0.00% |
Director
Nikolay Savchuk is COO Director of Traws Pharma
| Age | 56 |
| Address | 12 Penns Trail, Newtown, PA, United States, 18940 |
| Phone | 267 759 3680 |
| Web | https://www.trawspharma.com |
Nikolay Savchuk Latest Insider Activity
Tracking and analyzing the buying and selling activities of Nikolay Savchuk against Traws Pharma stock is an integral part of due diligence when investing in Traws Pharma. Nikolay Savchuk insider activity provides valuable insight into whether Traws Pharma is net buyers or sellers over its current business cycle. Note, Traws Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Traws Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Nikolay Savchuk over two months ago Acquisition by Nikolay Savchuk of 885532 shares of Traws Pharma at 0.01 subject to Rule 16b-3 | ||
Nikolay Savchuk over six months ago Acquisition by Nikolay Savchuk of 4801 shares of Traws Pharma subject to Rule 16b-3 | ||
Nikolay Savchuk over six months ago Insider Trading |
Traws Pharma Management Efficiency
The company has return on total asset (ROA) of (0.5251) % which means that it has lost $0.5251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9652) %, meaning that it created substantial loss on money invested by shareholders. Traws Pharma's management efficiency ratios could be used to measure how well Traws Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2025. Return On Capital Employed is likely to climb to -1.65 in 2025. At this time, Traws Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.2 M in 2025, whereas Non Currrent Assets Other are likely to drop 855.00 in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Katherine Blair | Skechers USA | 50 | |
| John Murphy | Summit Materials | 70 | |
| Bradley Weston | Boot Barn Holdings | 55 | |
| Christopher Bruzzo | Boot Barn Holdings | 50 | |
| Lisa Laube | Boot Barn Holdings | 58 | |
| Richard Carucci | Kontoor Brands | 61 | |
| Juliana Chugg | Kontoor Brands | 52 | |
| Joseph Cantie | Summit Materials | 57 | |
| David Weinberg | Skechers USA | 74 | |
| Mark Schiller | Kontoor Brands | 59 | |
| Steven Wunning | Summit Materials | 70 | |
| Anne Wade | Summit Materials | 48 | |
| Gregory Bettinelli | Boot Barn Holdings | 48 | |
| Gene Burt | Boot Barn Holdings | 54 | |
| Richard Rappaport | Skechers USA | 60 | |
| Morton Erlich | Skechers USA | 75 | |
| Geyer Kosinski | Skechers USA | 54 | |
| Brenda Morris | Boot Barn Holdings | 55 | |
| Anne MacDonald | Boot Barn Holdings | 65 | |
| Anne Cooney | Summit Materials | 61 | |
| Susan Ellerbusch | Summit Materials | 53 | |
Management Performance
| Return On Equity | -10.97 | ||||
| Return On Asset | -0.53 |
Traws Pharma Leadership Team
Elected by the shareholders, the Traws Pharma's board of directors comprises two types of representatives: Traws Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Traws. The board's role is to monitor Traws Pharma's management team and ensure that shareholders' interests are well served. Traws Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Traws Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Acting Officer | ||
| DPHIL MA, Executive Chairman | ||
| Mark CPA, Chief Officer | ||
| Victor MD, Chief Oncology | ||
| Steven MD, President Oncology | ||
| Nikolay Savchuk, COO Director | ||
| Charles Pauza, Chief Virology | ||
| Werner Cautreels, CEO Director | ||
| C Pauza, Chief Virology |
Traws Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Traws Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.97 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (103.23) % | ||||
| Current Valuation | (8.03 M) | ||||
| Shares Outstanding | 25.31 M | ||||
| Shares Owned By Insiders | 14.62 % | ||||
| Shares Owned By Institutions | 11.40 % | ||||
| Number Of Shares Shorted | 171.87 K | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 39.17 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.